Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.61 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406370 | 0.89 | PARK7 (0.76) | CHRM5ALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL578232 | 0.89 | PARK7 (0.76) | CHRM5ALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL9098074 | 0.84 | ALDH1A1 (0.61) | ALDH1A1ALDH3A1PARK7ACHE | |
| SCHEMBL28365902 | 0.83 | TDP1 (0.50) | CHRM5ALDH1A1PARK7CASP3TDP1 | |
| SCHEMBL29460856 | 0.83 | CASP3 (0.76) | CHRM5ALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL2305451 | 0.83 | CASP3 (0.76) | CHRM5ALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL4597561 | 0.82 | ALDH1A1 (0.74) | CHRM5ALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL4728227 | 0.81 | TDP1 (0.66) | ALDH1A1PARK7CASP3TDP1CA2 | |
| SCHEMBL27866584 | 0.81 | ALDH1A1 (0.67) | CHRM5ALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL4782178 | 0.81 | CHRM5 (0.68) | CHRM5ALDH1A1ALDH3A1ALDH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459390-B | 3-Hydroxy oxindole derivative containing Z-type 1, 4-dicarbonyl olefin, and preparation method and application thereof | SUN YAT-SEN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-118459390-A | 3-Hydroxy oxindole derivative containing Z-type 1, 4-dicarbonyl olefin, and preparation method and application thereof | 中山大学 | 2024-08-09 | — | — | CN | disclosed |
| CN-112920191-B | Arylethynyl oxindole oxirane as well as preparation method and application thereof | 南宁师范大学 | 2022-03-25 | — | — | CN | disclosed |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-19 | — | — | US | disclosed |
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CLEVELAND CLINIC FOUND (US) | 2017-08-17 | — | — | US | disclosed |
| US-9656957-B2 | Hydrazone modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150313874-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-11-05 | — | — | US | disclosed |
| US-9079854-B2 | Hydrazone modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130184275-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2013-07-18 | — | — | US | disclosed |
| US-8309595-B2 | Hydrazone modulators of cannabinoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100197755-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-05 | — | — | US | disclosed |
| WO-2009012227-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CHRM5 395/4885ALDH1A1 2096/4885ALDH3A1 1544/4885 |
| US-20150313874-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CHRM5 395/4885ALDH1A1 2096/4885ALDH3A1 1544/4885 |
| US-20100197755-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CHRM5 395/4885ALDH1A1 2096/4885ALDH3A1 1544/4885 |
| US-20130184275-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CHRM5 395/4885ALDH1A1 2096/4885ALDH3A1 1544/4885 |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CHRM5 395/4885ALDH1A1 2096/4885ALDH3A1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.